Bio­haven cel­e­brates PhII/III win for in­tranasal CGRP mi­graine drug amid oral race with Al­ler­gan

In the run-up to an FDA de­ci­sion on its mi­graine pill, Bio­haven is bran­dish­ing a sec­ond weapon from its CGRP ar­se­nal — an in­tranasal for­mu­la­tion — that it says has hit the main goals of a Phase II/III tri­al.

Three dos­es were test­ed in the study, and the two high­er dos­es (10mg and 20mg) beat place­bo on the co-pri­ma­ry end­points of pain free­dom and free­dom from most both­er­some symp­toms at 2 hours. Mean­while, the 5mg dose didn’t make a sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER